ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,271.38
      1.38%
      US Tech 100
      17,571.20
      1.04%
      Dow Jones
      39,250.04
      1.26%
      Brent Oil
      77.90
      -0.61%
      Bitcoin
      57,467.74
      4.43%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Rhythm Pharmaceuticals Inc (RYTM)

      7. Rhythm Pharmaceuticals Inc (RYTM) News

      RYTM

      Rhythm Pharmaceuticals (RYTM)

      Rhythm Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:RYTM
      DateTimeSourceHeadlineSymbolCompany
      08/07/20246:03AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RYTMRhythm Pharmaceuticals Inc
      08/07/20246:00AMEdgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RYTMRhythm Pharmaceuticals Inc
      08/06/20244:21PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
      08/06/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RYTMRhythm Pharmaceuticals Inc
      08/06/20247:00AMGlobeNewswire Inc.Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/31/20249:10AMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years OldNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/30/20245:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/23/20248:00AMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic ObesityNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/23/20247:30AMGlobeNewswire Inc.Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/18/20245:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/16/20244:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/16/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/12/20244:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/11/20244:01PMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces New Employment Inducement GrantsNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/10/20245:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/10/20245:00PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/10/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/10/20244:05PMEdgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
      07/08/20248:00AMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific OfficerNASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/28/20248:00AMGlobeNewswire Inc.Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR DeficiencyNASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/17/20245:28PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/17/20245:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/11/20244:01PMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces New Employment Inducement GrantsNASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/03/20244:02PMGlobeNewswire Inc.Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
      06/03/20248:02AMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferenceNASDAQ:RYTMRhythm Pharmaceuticals Inc
      05/22/20244:00AMGlobeNewswire Inc.Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl SyndromeNASDAQ:RYTMRhythm Pharmaceuticals Inc
      05/13/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      05/09/20244:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
      05/09/20244:01PMGlobeNewswire Inc.Rhythm Pharmaceuticals Announces New Employment Inducement GrantsNASDAQ:RYTMRhythm Pharmaceuticals Inc
      05/07/20244:43PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:RYTM

      Your Recent History

      LSE
      PYM
      Phytopharm
      Delayed Upgrade Clock